{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:46:00Z","timestamp":1789055160023,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Zolbetuximab combined with fluoropyrimidine\u2013oxaliplatin chemotherapy has demonstrated clinical benefit in CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma (GC\/GEJC). In clinical practice, however, gastrointestinal toxicity and serum albumin decline are frequently encountered during treatment, and the relationship between early albumin kinetics and antitumor efficacy remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective exploratory study of patients with unresectable or recurrent CLDN18.2-positive GC\/GEJC treated with zolbetuximab-based chemotherapy between July 2024 and August 2025. Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in patients with measurable disease. The objective response rate (ORR) and early tumor shrinkage (ETS \u226520%) were assessed. Serum albumin kinetics were analyzed using baseline albumin, landmark nadir albumin measured at or immediately before the first radiological evaluation, and relative change in albumin from baseline (\u0394Alb). Associations between albumin metrics and tumor response were explored using exploratory analyses, including continuous-variable modeling. Relative dose intensity and chemotherapy backbone (CAPOX vs FOLFOX) were also descriptively examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 38 eligible patients, 24 had measurable disease and were evaluable for RECIST-based response. Partial response was observed in 18 patients, yielding an ORR of 75.0% (95% CI, 55.1\u201388.0). Early tumor shrinkage \u226520% was achieved in a proportion of evaluable cases. Baseline serum albumin showed a moderate positive correlation with landmark nadir albumin (Spearman\u2019s \u03c1\u00a0=\u00a00.35, P\u00a0=\u00a0.030) and with \u0394Alb (\u03c1\u00a0=\u00a00.52, P\u00a0=\u00a0.0007), indicating that patients with higher baseline albumin tended to experience greater absolute albumin decline. Neither landmark nadir albumin nor \u0394Alb was significantly associated with the ORR or ETS. Early reductions in serum albumin were frequently observed during initial treatment cycles but did not correspond to impaired tumor response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world exploratory cohort, zolbetuximab-based chemotherapy achieved objective tumor responses consistent with prior clinical trials. Early serum albumin decline was not associated with inferior tumor response. These findings suggest that early albumin decline should not be interpreted as a surrogate marker of treatment failure or reduced antitumor efficacy but rather as a treatment-related physiological change. Prospective studies are warranted to clarify the clinical implications of albumin dynamics and optimize supportive care during anti-CLDN18.2 therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag024","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:37:16Z","timestamp":1769863036000},"page":"695-703","source":"Crossref","is-referenced-by-count":2,"title":["Zolbetuximab-based chemotherapy in CLDN18.2-positive gastric cancer: real-world tumor response and early albumin kinetics"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0980","authenticated-orcid":false,"given":"Yuki","family":"Ushimaru","sequence":"first","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitomo","family":"Yanagimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Masuike","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4645-2056","authenticated-orcid":false,"given":"Takahito","family":"Sugase","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanemura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Sakano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kitakaze","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisateru","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Miyo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Sueda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihito","family":"Gotoh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute , 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"2026060509363289900_ref1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/d41573-024-00172-7","article-title":"FDA approves first claudin-18.2-targeted antibody for gastric cancer","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026060509363289900_ref2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3390\/cancers16030679","article-title":"Claudin 18.2 as a new biomarker in gastric cancer-what should we know?","volume":"16","author":"Mathias-Machado","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026060509363289900_ref3","doi-asserted-by":"publisher","first-page":"1132319","DOI":"10.3389\/fonc.2023.1132319","article-title":"Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"2026060509363289900_ref4","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"key":"2026060509363289900_ref5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.46883\/2024.25921031","article-title":"Efficacy and safety of Zolbetuximab in gastric cancer","volume":"38","author":"Waheed","year":"2024","journal-title":"Oncology (Williston Park)"},{"key":"2026060509363289900_ref6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/17460441.2024.2370332","article-title":"The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer","volume":"19","author":"Zeng","year":"2024","journal-title":"Expert Opin Drug Discov"},{"key":"2026060509363289900_ref7","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"2026060509363289900_ref8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet (London, England)"},{"key":"2026060509363289900_ref9","doi-asserted-by":"publisher","first-page":"e16069","DOI":"10.1200\/JCO.2025.43.16_suppl.e16069","article-title":"Unlocking the potential of zolbetuximab in CLDN18.2-positive gastric cancer: a comprehensive systematic review of clinical efficacy and safety","volume":"43","author":"Gul","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026060509363289900_ref10","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1080\/14796694.2024.2342107","article-title":"Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary","volume":"20","author":"Shitara","year":"2024","journal-title":"Future Oncol"},{"key":"2026060509363289900_ref11","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJMc2409512","article-title":"Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma","volume":"391","author":"Shitara","year":"2024","journal-title":"N Engl J Med"},{"key":"2026060509363289900_ref12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026060509363289900_ref13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","article-title":"RECIST 1.1 - standardisation and disease-specific adaptations: perspectives from the RECIST working group","volume":"62","author":"Schwartz","year":"1990","journal-title":"Eur J Cancer"},{"key":"2026060509363289900_ref14","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s10120-025-01668-w","article-title":"Gallbladder edema as a clue to zolbetuximab-associated protein-losing enteropathy in gastric cancer: a case report","volume":"28","author":"Kakiuchi","year":"2025","journal-title":"Gastric Cancer"},{"key":"2026060509363289900_ref15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s13691-025-00764-z","article-title":"A case of zolbetuximab-induced protein-losing gastroenteropathy in a patient with advanced gastric cancer","volume":"14","author":"Tsuji","year":"2025","journal-title":"Int Cancer Conf J"},{"key":"2026060509363289900_ref16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/jjco\/hyaf055","article-title":"Two cases of protein-losing enteropathy induced by zolbetuximab in patients with unresectable advanced gastric cancer","volume":"55","author":"Yanagimoto","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"2026060509363289900_ref17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet (London, England)"},{"key":"2026060509363289900_ref18","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","article-title":"Efficacy of reduced-intensity chemotherapy with Oxaliplatin and Capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial","volume":"7","author":"Hall","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026060509363289900_ref19","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/sj.bjc.6603046","article-title":"A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer","volume":"94","author":"Park","year":"2006","journal-title":"Br J Cancer"},{"key":"2026060509363289900_ref20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1758834009355164","article-title":"Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management","volume":"2","author":"Stein","year":"2010","journal-title":"Ther Adv Med Oncol"},{"key":"2026060509363289900_ref21","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","article-title":"Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer","volume":"8","author":"Kubota","year":"2023","journal-title":"ESMO Open"},{"key":"2026060509363289900_ref22","doi-asserted-by":"publisher","first-page":"e2300543","DOI":"10.1200\/PO.23.00543","article-title":"Retrospective study of Claudin 18 isoform 2 prevalence and prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma","volume":"8","author":"Waters","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2026060509363289900_ref23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-024-01595-w","article-title":"Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting","volume":"17","author":"Zhou","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2026060509363289900_ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","journal-title":"Gastric Cancer"},{"key":"2026060509363289900_ref25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN clinical practice guidelines In oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Cancer Netw"},{"key":"2026060509363289900_ref26","doi-asserted-by":"publisher","first-page":"155145","DOI":"10.1016\/j.prp.2024.155145","article-title":"Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: a literature review with expert opinion","volume":"254","author":"Angerilli","year":"2024","journal-title":"Pathol Res Pract"},{"key":"2026060509363289900_ref27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s13691-025-00804-8","article-title":"Conversion surgery following zolbetuximab-based chemotherapy for CLDN18.2-positive gastroesophageal junction cancer","volume":"14","author":"Ushimaru","year":"2025","journal-title":"Int Cancer Conf J"},{"key":"2026060509363289900_ref28","doi-asserted-by":"publisher","first-page":"100257","DOI":"10.1016\/j.esmogo.2025.100257","article-title":"Hypoalbuminemia during zolbetuximab plus chemotherapy for claudin 18.2-positive advanced gastric cancer: a need for caution? ESMO","volume":"10","author":"Shimozaki","year":"2025","journal-title":"Gastrointest Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/6\/695\/66892029\/hyag024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/6\/695\/66892029\/hyag024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:36:40Z","timestamp":1780666600000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/6\/695\/8482831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,13]]},"published-print":{"date-parts":[[2026,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag024","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,2,13]]}}}